ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ClinicalTrials.gov
Last refreshed on:	7 February 2022
Main ID:	NCT02021695
Date of registration:	22/11/2013
Prospective Registration:	No
Primary sponsor:	Weill Medical College of Cornell University
Public title:	DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes
Scientific title:	DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes
Date of first enrolment:	September 2013
Target sample size:	249
Recruitment status:	Completed
URL:	https://clinicaltrials.gov/show/NCT02021695
Study type:	Observational
Study design:
Phase:

Countries of recruitment
Qatar

Contacts

Name:	Charbel Abi Khalil, MD
Address:
Telephone:
Email:
Affiliation:	Weill Cornell Medical College in Qatar

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Must provide informed consent

2. Males or Females aged 30 years or older to minimize the potential confounding of other
forms of diabetes mellitus

3. In patients with diabetes, no concomitant diseases except for micro- and macrovascular
complications of diabetes (nephropathy, retinopathy, peripheral arterial disease,
coronary artery disease, neuropathy) or symptoms of the metabolic syndrome
(hypertension, dyslipidemia and obesity)

4. Not taking any chronic medications (except of the diabetes and cardiovascular related
drugs).

Exclusion Criteria:

1. Diagnosis of Type-I Diabetes

2. Active situational diabetes (steroids use/pregnancy)

3. Active infection or acute illness of any kind

4. Chronic inflammation (auto-immune diseases) or infection

5. Evidence of malignancy within the past 5 years

6. Chronic hematological disorders known to affect glycated hemoglobin results such as
hemoglobinopathies (e.g. sickle cell disease and thalassemia), increases red-cell
turnover (e.g. hemolytic anemia and spherocytosis.

- Evidence of malignancy within the past 5 years

- Chronic hematological disorders known to affect glycated hemoglobin results such
as hemoglobinopathies

Age minimum: 30 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Type 2 Diabetes

Intervention(s)

Primary Outcome(s)

DNA methylation and gene expression in blood monocytes and lymphocytes [Time Frame: 1 hour]

Secondary Outcome(s)

Secondary ID(s)

13-00023 [JIRB]

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Hamad Medical Corporation

Weill Cornell Medical College in Qatar

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.